Drospirenone
| Evidence Level: L5 | Predicted Indications: 52 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Drospirenone |
| DrugBank ID | DB01395 |
| Brand Names (EU) | Drospirenone, Lydisilka |
| Evidence Level | L5 |
| Predicted Indications | 52 |
| Top Prediction Score | 99.99% |
Approved Indication (EMA)
oral contraceptive
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | acne (disease) | 99.99% | DL |
| 2 | zinc, elevated plasma | 98.74% | DL |
| 3 | dyschondrosteosis-nephritis syndrome | 93.61% | DL |
| 4 | torticollis-keloids-cryptorchidism-renal dysplasia syndrome | 93.53% | DL |
| 5 | infundibulopelvic stenosis-multicystic kidney syndrome | 93.33% | DL |
| 6 | pyogenic arthritis-pyoderma gangrenosum-acne syndrome | 93.18% | DL |
| 7 | 46,XX disorder of sex development-anorectal anomalies syndrome | 92.77% | DL |
| 8 | thyrocerebrorenal syndrome | 92.76% | DL |
| 9 | acrorenal syndrome | 92.75% | DL |
| 10 | radial hypoplasia-triphalangeal thumbs-hypospadias-maxillary diastema syndrome | 92.67% | DL |
| 11 | Mayer-Rokitansky-Kuster-Hauser syndrome | 92.65% | DL |
| 12 | Guttmacher syndrome | 92.63% | DL |
| 13 | renal nutcracker syndrome | 92.63% | DL |
| 14 | nephrosis-deafness-urinary tract-digital malformations syndrome | 92.53% | DL |
| 15 | trisomy 13 | 92.50% | DL |
| 16 | Mayer-Rokitansky-Küster-Hauser syndrome type 2 | 92.36% | DL |
| 17 | pericardial and diaphragmatic defect | 92.33% | DL |
| 18 | diaphragmatic defect-limb deficiency-skull defect syndrome | 92.27% | DL |
| 19 | renal-genital-middle ear anomalies | 92.26% | DL |
| 20 | monosomy 13q34 | 92.25% | DL |
Showing top 20 of 52 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.